ascopubs.org14d
Real-world analysis of pembrolizumab utilization and characteristics of patients being prescribed treatment in early stage RCC.
Cabozantinib real-world effectiveness in the second-line setting of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
ascopubs.org5d
Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2024.3
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3 ...
ascopubs.org5d
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3
Reply to: Treatment Intensification Based on Residual Disease in Elderly Patients With AML ...
ascopubs.org14d
COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma A total of 121 patients (previous ICI-treated cohort, n = 31, and each of ...
ascopubs.org5d
Challenges in the Management of Advanced Prostate Cancer
Assessing Clinical Value of New Treatment Strategies: ESMO-MCBS and ASCO-VF Evaluation in Phase III Trials at ASCO Annual Meeting 2022 Fig 1. Challenges in the management of advanced prostate cancer.
ascopubs.org25d
Spotlight on Lung Cancer Disparities in India
The India State-Level Disease Burden Initiative partners revealed significant variation in age-standardized incidence of the top 10 malignancies, including LC from 1990 to 2016. In men, the crude LC ...
ascopubs.org14d
Clinical and radiographic trends in patients with renal angiomyolipomas (AML).
68Ga-FAPI-46 PET/CT for cancer imaging: Results of a single-center, prospective, interventional, single-arm clinical trial. Demographic and clinical characteristics of patients with renal AML: ...
ascopubs.org14d
Germline correlates of clinical outcomes in aggressive prostate cancer subtypes treated with radiation therapy.
Genomic alterations in intraductal prostate cancer: Insights from the Genomic Umbrella Neoadjuvant study (GUNS) in high-risk localized disease. This is an ASCO Meeting Abstract from the 2025 ASCO ...
ascopubs.org12d
Erratum: Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update Clinical Insights
How Should We Manage the Impact of Antimicrobial Resistance in Patients With Cancer? An Oncological and Infectious Disease Specialist Point of View ...
ascopubs.org14d
Genome-scale metabolic reconstruction of urinary microbiome: Pathway for personalized medicine.
TP53 Y220C mutations in advanced urothelial bladder cancer (UBC): A genomic landscape study. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does not ...
ascopubs.org13d
Reply to: Enfortumab Vedotin: A Promising Therapy for Head and Neck Cancer With Potential Links to Human Papillomavirus
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
ascopubs.org14d
Estimation of overall survival in immunotherapy-treated bladder cancer using computer vision.
Immune and inflammatory profiling in bladder cancer: Insights into biomarkers and therapeutic strategies. Spatial transcriptomic analysis of tumor tissue from patients with metastatic urothelial ...